innovation participation platform

about

Research organizations of various types produce a steady supply of discoveries that are promising but not yet investable. Between laboratory validation and commercial readiness lies a stage of work that research grants are rarely designed to fund and that venture capital generally considers too early: lead optimization, toxicology, and IND-enabling studies for a therapeutic; prototyping, pilot-scale manufacturing, and industry certification for a new material or energy technology. University proof-of-concept grants typically range from about $50,000 to $500,000, and even ARPA-E awards average roughly $2 million to $4 million. Advancing a single therapeutic program to IND readiness commonly requires $5 million to $25 million, however. Many discoveries stall in the difference.

The platform is a proposed financial product for this stage of development. Participants, among them alumni, family offices, foundations, and other mission-oriented supporters, commit capital to a professionally managed vehicle that funds a portfolio of roughly eight to twelve translational programs at a research institution. In exchange, the vehicle receives revenue participation interests in the funded intellectual property: a share of what the institution realizes from license fees, milestone payments, sublicensing, royalties, partnerships, or acquisition. It takes no equity in the research or in any company spun out of it. Capital is released in stages over five to seven years as programs meet predefined technical and commercial milestones; programs that miss milestones are modified, paused, or discontinued.

Participant returns are capped. In the illustrative model, the vehicle receives 20 percent of commercialization proceeds from a class of programs until participants have received three times their invested capital; everything beyond that remains with the originating institution. The cap is the point of the design. It offers enough return to attract patient private capital to a portfolio in which most programs, as is normal in early-stage development, will not reach the market, while ensuring that an extraordinary success accrues in large part to the originating institution, its inventors, and its future research rather than to its financiers. Reinvested, those proceeds let one generation of discoveries help pay for the next.

Selection is kept apart from both institutional politics and the incentives of conventional fund management. A committee chaired by senior institutional leadership nominates candidate programs. An independent Technical and Commercial Advisory Board, whose members have no affiliation with the recipient laboratories, evaluates and approves them, and both bodies must confirm each milestone before further capital is released. The model is set out in two papers: one for biotechnology and the life sciences, where the target is IND readiness, and one for clean energy, climate technology, and advanced materials, where the target is advancement from early laboratory validation (Technology Readiness Levels 3–4) to pilot-scale demonstration (TRLs 6–7), with up to $10 million per program.

‍
Learn more about the academic innovation participation products:

Innovation Participation Platform: A New Financial Product to Accelerate Biotechnology Innovation / Geoffrey W. Smith & Samuel Waxman / July 2026

Innovation Participation Platform: A New Financial Product to Accelerate DeepTech Innovation / Geoffrey W. Smith & Samuel Waxman / July 2026